Publications by authors named "N van Zandwijk"
Asbestos, a group of class I (WHO) carcinogenic fibers, is the main cause of mesothelioma. Asbestos inhalation also increases the risk to develop other solid tumours with lung cancer as the most prominent example [91]. The incidence of asbestos-related lung cancer (ARLC) is estimated to be to six times larger than the mesothelioma incidence thereby becoming an important health issue [86].
View Article and Find Full Text PDFArticle Synopsis
- Small cell lung cancer (SCLC) has a very low 5-year survival rate of less than 7%, even with the inclusion of new immunotherapy treatments alongside chemotherapy.
- Specific biomarkers like DLL3 and SLFN11 could help identify more effective targeted therapies, such as bispecific monoclonal antibodies and PARP inhibitors.
- The use of circulating tumor cells (CTCs) from blood tests presents a potentially easier approach for gaining insights into SCLC and guiding treatment decisions, but their effectiveness for this purpose is still being researched.
Article Synopsis
- - All six types of asbestos are capable of causing diseases, including lung cancer, related to exposure.
- - The dangers of asbestos became apparent in the 1890s, with growing awareness and research about its health risks over time.
- - Major use of asbestos surged in the mid-20th century, particularly in construction and shipbuilding, with lung cancer risks identified as early as the 1940s.
Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects of smoking and other carcinogens adds complexity to the diagnostic process. Compounding these challenges is the absence of a specific histopathologic or mutational signature of ARLC.
View Article and Find Full Text PDF